Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.
暂无分享,去创建一个
E. Antman | M. Sabatine | E. Braunwald | L. Newby | C. Cannon | E. Ohman | D. Morrow | S. Murphy | J. Januzzi | K. Pieper | David A. Morrow | L. K. Newby | E. Ohman | Christopher P. Cannon
[1] L. Newby,et al. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. , 2005, Annals of emergency medicine.
[2] Deepak L. Bhatt,et al. Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .
[3] M. Sabatine,et al. Elevation in Serum Troponin I Predicts the Benefit of Tirofiban , 2001, Journal of Thrombosis and Thrombolysis.
[4] R. Califf,et al. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. , 2002, American heart journal.
[5] B. Lindahl,et al. A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation. , 2002, American heart journal.
[6] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[7] E. Antman,et al. Decision making with cardiac troponin tests. , 2002, The New England journal of medicine.
[8] R. Califf,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.
[9] L. Wallentin,et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. , 2002, Journal of the American College of Cardiology.
[10] E. Braunwald,et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.
[11] E. Antman. Troponin measurements in ischemic heart disease: more than just a black and white picture. , 2001, Journal of the American College of Cardiology.
[12] V. Hasselblad,et al. Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy , 2001, Circulation.
[13] K. Thygesen,et al. Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .
[14] E. Antman,et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. , 2000, Journal of the American College of Cardiology.
[15] R. Giugliano,et al. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. , 2000, The American journal of cardiology.
[16] Hugo A. Katus,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.
[17] H. White,et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban , 1999, The Lancet.
[18] C. Heeschen,et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.
[19] E. Cook,et al. A proposed strategy for utilization of creatine kinase-MB and troponin I in the evaluation of acute chest pain. , 1999, The American journal of cardiology.
[20] K. Lee,et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. , 1998, Circulation.
[21] E. Cook,et al. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. , 1998, Journal of the American College of Cardiology.
[22] R. Califf,et al. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes , 1998 .
[23] F. Harrell,et al. Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .
[24] D Wybenga,et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.
[25] L. Wilkins. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.
[26] J. Mcmanus. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .
[27] L. Wilkins. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.